Vor Biopharma Inc. (VOR)
| Market Cap | 1.37B +405.2% |
| Revenue (ttm) | n/a |
| Net Income | 627.78M |
| EPS | 20.19 |
| Shares Out | 59.16M |
| PE Ratio | 1.14 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 89,000 |
| Open | 22.82 |
| Previous Close | 23.01 |
| Day's Range | 22.82 - 23.66 |
| 52-Week Range | 6.50 - 50.20 |
| Beta | 1.72 |
| Analysts | Strong Buy |
| Price Target | 39.00 (+68.47%) |
| Earnings Date | Aug 11, 2026 |
About VOR
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren’s disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for VOR stock is "Strong Buy." The 12-month stock price target is $39.0, which is an increase of 68.47% from the latest price.
News
Vor Bio price target raised to $27 from $18 at Wedbush
Wedbush raised the firm’s price target on Vor Bio (VOR) to $27 from $18 and keeps a Neutral rating on the shares. The firm notes the company reported earnings and…
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of teli...
Vor Biopharma Quarterly report: Q2 2026
Vor Biopharma has published its Q2 2026 quarterly earnings report on August 11, 2026.
Vor Biopharma Earnings release: Q2 2026
Vor Biopharma released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on August 1, 2026, the ...
Vor Bio Appoints David Zaccardelli to Board of Directors
BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David Zacc...
Vor Bio announces China NMPA approval for telitacicept
Vor Bio (VOR) and RemeGen announced that China’s National Medicinal Products Administration, or NMPA, has conditionally approved telitacicept for the treatment of adult patients with IgAN.
Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China
First regulatory approval for Sjögren's disease (SjD) First and only approved therapy for SjD in China Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating statis...
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published in ...
Vor Biopharma Transcript: Jefferies Global Healthcare Conference 2026
Telitacicept, a dual BAFF/APRIL inhibitor, is advancing through global phase III trials for gMG and Sjögren's, leveraging robust efficacy and safety data from China. Positioned for first- or second-line use in large, rapidly growing markets, the company maintains a strong cash runway and commercial focus.
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corpora...
Vor Bio price target raised to $18 from $15 at Wedbush
Wedbush analyst Martin Fan raised the firm’s price target on Vor Bio (VOR) to $18 from $15 and keeps a Neutral rating on the shares. The firm notes the company…
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment Results further support the potential for telitacicept ...
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of teli...
Vor Biopharma Quarterly report: Q1 2026
Vor Biopharma has published its Q1 2026 quarterly earnings report on May 13, 2026.
Vor Biopharma Earnings release: Q1 2026
Vor Biopharma released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Vor Bio files to sell 5.34M shares of common stock for holders
16:13 EDT Vor Bio (VOR) files to sell 5.34M shares of common stock for holders
Vor Biopharma Proxy statement: Proxy filing
Vor Biopharma filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Vor Biopharma Proxy statement: Proxy filing
Vor Biopharma filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Vor Biopharma Registration statement: Registration filing
Vor Biopharma filed a registration statement on April 27, 2026, providing details about a securities offering with the SEC.
Vor Bio price target lowered to $31 from $32 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Vor Bio (VOR) to $31 from $32 and keeps a Buy rating on the shares. The firm says the company has “undergone…
Vor Bio price target raised to $15 from $9 at Wedbush
Wedbush raised the firm’s price target on Vor Bio (VOR) to $15 from $9 and keeps a Neutral rating on the shares. The firm notes the company reported earnings and…
Vor Bio price target lowered to $40 from $55 at Stifel
Stifel lowered the firm’s price target on Vor Bio (VOR) to $40 from $55 and keeps a Buy rating on the shares. The global Phase 3 UPSTREAM MG trial evaluating…
Vor Bio price target lowered to $40 from $55 at Stifel
Stifel lowered the firm’s price target on Vor Bio (VOR) to $40 from $55 and keeps a Buy rating on the shares. The global Phase 3 UPSTREAM MG trial evaluating…
Vor Bio doses first patient in UPSTREAM SjD study
Vor Bio (VOR) announced the dosing of the first patient in UPSTREAM SjD, a global, randomized, double-blind, placebo-controlled Phase 3 trial evaluating telitacicept in adult patients with active prim...